Targeting airway inflammation: PMX464 and the epithelial bulls eye

British Journal of Pharmacology

Volumn 155, Issue 5, 2008, Pages 620-622

  Sexton, D W ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

3D culture; Airway epithelial cell; Airway inflammation; Drug screening; NF B; PMX464; Thioredoxin; Thioredoxin reductase

Indexed keywords

I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PMX 464; PROTEIN INHIBITOR; SMALL INTERFERING RNA; THIOL REACTIVE QUINOL; THIOREDOXIN; THIOREDOXIN INHIBITOR; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CELL STRAIN; CELL TYPE; CULTURE TECHNIQUE; DRUG EFFECT; DRUG TARGETING; ENZYME REPRESSION; EPITHELIUM CELL; HUMAN; HUMAN CELL; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFLAMMATION; TARGET CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOTHIAZOLES; CELL LINE, TUMOR; CYCLOHEXANONES; EPITHELIAL CELLS; HUMANS; IMMUNITY, INNATE; OXIDATION-REDUCTION; RESPIRATORY MUCOSA;

EID: 54949138058     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.290     Document Type: Note

References (12)

1. Callister ME, Pinhu L, Catley MC, Westwell AD, Newton R, Leaver SK et al. (2008). PMX464, a thiol-reactive quinol and putative thioredoxin inhibitor, inhibits NF-kB-dependent proinflammatory activation of alveolar epithelial cells. Br J Pharmacol 155: 659-670 (this issue).
2. Hayday A, Viney JL (2000). The ins and outs of body surface immunology. Science 290: 97-100.
3. Henderson Jr WR, Chi EY, Teo JL, Nguyen C, Kahn M (2002). A small molecule inhibitor of redox-regulated NF-kappa B and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model. J Immunol 169: 5294-5299.
4. Holgate ST (2008). The airway epithelium is central to the pathogenesis of asthma. Allergol Int 57: 1-10.
5. Ichiki H, Hoshino T, Kinoshita T, Imaoka H, Kato S, Inoue H et al. (2005). Thioredoxin suppresses airway hyperresponsiveness and airway inflammation in asthma. Biochem Biophys Res Commun 334: 1141-1148.
6. Pennington JD, Jacobs KM, Sun L, Bar-Sela G, Mishra M, Gius D (2007). Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Curr Pharm Des 13: 3368-3377.
7. Rahman I, Biswas SK, Kode A (2006). Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 533: 222-239.
8. Rancourt RC, Lee RL, O'Neill H, Accurso FJ, White CW (2007). Reduced thioredoxin increases proinflammatory cytokines and neutrophil influx in rat airways: modulation by airway mucus. Free Radic Biol Med 42: 1441-1453.
9. Soini Y, Kahlos K, Näpänkangas U, Kaarteenaho-Wiik R, Säily M, Koistinen P et al. (2001). Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Research 7: 1750-1757.
10. Stick SM, Holt PG (2003). The airway epithelium as immune modulator. The LARC Ascending. Am J Respir Cell Mol Biol 28: 641-644.
11. Walsh GM, Sexton DW, Blaylock MG (2003). Eosinophils, bronchial epithelial cells and steroids - new insights into the resolution of inflammation in asthma. J Endocrinology 178: 37-43.
12. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C et al. (1997). Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137: 231-245.